- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03295903
Cannabinoid Supplementation on Vascular and Cognitive Function
21. oktober 2019 opdateret af: Phil Ainslie, University of British Columbia
The Effects of Cannabinoids on Vascular and Cognitive Function in Young and Old Healthy Adults.
Cannabidiol (CBD) is a bioactive cannabinoid compound in marijuana (cannabis sativa), but unlike Δ9 tetrahydrocannabinol (THC), lacks the psychoactivity effect of THC.
Available evidence suggests that there are marked therapeutic CBD effects for diverse disease processes including inflammation, cancers, psychosis, and epileptic seizures.
The purpose of this study, in both younger and older healthy humans, is to improve our understanding of how CBD might control and regulate blood vessel health as well as cognitive and exercise performance.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
24
Fase
- Tidlig fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Ontario
-
Kelowna, Ontario, Canada, V1V 1V7
- University of British Columbia
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- non-smoking
- non-obese
- between the ages of 18-30 & 60-75 years
- have no history of cardiopulmonary, liver, gastrointestinal, kidney or cerebrovascular disease.
Exclusion Criteria:
- are obese
- are taking prescription drugs or over-the-counter supplements that influence cardiovascular or nitric oxide metabolism
- have a history of smoking
- have history of cardiovascular, respiratory (including asthma) or neurological disease
- have known intolerance to ginseng or ginkgo herbals
- have kidney, gastrointestinal or liver disease
- have epilepsy
- have diabetes
- are pregnant or breast feeding
- do not speak English as first language
- a student in the University of British Columbia (UBC) Okanagan Centre for Heart, Lung and Vascular Health
- medical or recreational use of cannabis
- clinically diagnosed anxiety or depression
- history of opioid use
- unwilling or unable to execute the informed consent documentation
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
Sugar pill that will have no effect.
|
Subjects will be administered in a double-blinded, randomized and cross-over design
|
|
Aktiv komparator: Cannabidiol and herbal capsules (1 dose)
Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
|
Subjects will be administered in a double-blinded, randomized and cross-over design
|
|
Aktiv komparator: Cannabidiol (1 dose)
Only cannabidiol supplement.
|
Subjects will be administered in a double-blinded, randomized and cross-over design
|
|
Aktiv komparator: Cannabidiol and herbal capsules (2 dose)
Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
|
Subjects will be administered in a double-blinded, randomized and cross-over design
|
|
Aktiv komparator: Cannabidiol only (2 dose)
Only cannabidiol supplement.
|
Subjects will be administered in a double-blinded, randomized and cross-over design
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Circulating cannabidiol and nitric oxide markers
Tidsramme: Through study completion, an average of 1 year
|
Measured by venous blood sampling
|
Through study completion, an average of 1 year
|
|
Vascular function
Tidsramme: Through study completion, an average of 1 year
|
Duplex ultrasound system
|
Through study completion, an average of 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hjerterytme
Tidsramme: Gennem studieafslutning i gennemsnit 1 år
|
Målt med 3-aflednings elektrokardiogram
|
Gennem studieafslutning i gennemsnit 1 år
|
|
Height
Tidsramme: Through study completion, an average of 1 year
|
Height in cm
|
Through study completion, an average of 1 year
|
|
Weight
Tidsramme: Through study completion, an average of 1 year
|
Weight in kg
|
Through study completion, an average of 1 year
|
|
Body mass index
Tidsramme: Through study completion, an average of 1 year
|
Body mass in kilograms divided by height in meters squared
|
Through study completion, an average of 1 year
|
|
Systolic blood pressure
Tidsramme: Through study completion, an average of 1 year
|
Measured by automated sphygmomanometer
|
Through study completion, an average of 1 year
|
|
Diastolic blood pressure
Tidsramme: Through study completion, an average of 1 year
|
Measured by automated sphygmomanometer
|
Through study completion, an average of 1 year
|
|
Respiration
Tidsramme: Through study completion, an average of 1 year
|
Measured by spirometry
|
Through study completion, an average of 1 year
|
|
Medical History Questionnaire
Tidsramme: Through study completion, an average of 1 year
|
Assesses inclusion/exclusion criteria and prior history of medical conditions.
|
Through study completion, an average of 1 year
|
|
Gastrointestinal Distress Questionnaire
Tidsramme: Through study completion, an average of 1 year
|
Measured using a 10 cm visual analogue scale
|
Through study completion, an average of 1 year
|
|
Anxiety Questionnaire
Tidsramme: Through study completion, an average of 1 year
|
Assessed with a visual analog scale
|
Through study completion, an average of 1 year
|
|
Cognitive performance
Tidsramme: Through study completion, an average of 1 year
|
Computerized battery of neuropsychological tests
|
Through study completion, an average of 1 year
|
|
Exercise performance
Tidsramme: Through study completion, an average of 1 year
|
Step-wise exercise test on cycle ergometer
|
Through study completion, an average of 1 year
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. januar 2018
Primær færdiggørelse (Forventet)
30. september 2021
Studieafslutning (Forventet)
1. oktober 2021
Datoer for studieregistrering
Først indsendt
20. september 2017
Først indsendt, der opfyldte QC-kriterier
22. september 2017
Først opslået (Faktiske)
28. september 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
23. oktober 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
21. oktober 2019
Sidst verificeret
1. oktober 2019
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- H17-01957
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
Individual values will be reported in figures if applicable.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kostændring
-
Necmettin Erbakan UniversityAktiv, ikke rekrutterendeParadentose | MIDDELHAVS-DIETKalkun
-
Tel Aviv UniversityAfsluttetAttention Bias Modification Treatment (ABMT)Israel
Kliniske forsøg med Cannabidiol supplement
-
London Metropolitan UniversityRekrutteringLivskvalitet | Seksuel adfærd | Velvære, psykologisk | Seksuel smerteforstyrrelseDet Forenede Kongerige
-
Marius HenriksenAfsluttet
-
Hannah HarrisNational Institute on Drug Abuse (NIDA)RekrutteringCannabis | Eksperimentel smerte hos raske menneskelige deltagere | MisbrugsansvarForenede Stater
-
University of Colorado, BoulderRekrutteringDepression | Smerte | Søvn | AngstForenede Stater
-
University of Colorado, BoulderRekrutteringDepression | Smerte | Søvn | AngstForenede Stater
-
University of Colorado, BoulderNational Institute on Drug Abuse (NIDA)RekrutteringMisbrug af cannabisForenede Stater
-
Elena PopeAvicanna IncTrukket tilbageSmerte | Epidermolyse Bullosa | KløeCanada
-
Zynerba Pharmaceuticals, Inc.Aktiv, ikke rekrutterendeFragilt X syndromForenede Stater, Det Forenede Kongerige, New Zealand, Australien
-
University of Northern ColoradoAfsluttet
-
Pure GreenAfsluttetMuskuloskeletale smerterForenede Stater